David Lebovitz
Stock Analyst at Citigroup
(3.22)
# 1,020
Out of 4,876 analysts
95
Total ratings
65.62%
Success rate
7.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $82 → $78 | $54.60 | +42.86% | 4 | May 2, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $338 → $351 | $316.95 | +10.74% | 31 | Mar 21, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $378 → $469 | $307.22 | +52.66% | 4 | Feb 27, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $30.35 | +143.86% | 2 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $50.64 | -24.96% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $49.55 | -65.69% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $128.21 | -28.24% | 6 | Feb 1, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $61.93 | -12.80% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $39.90 | -12.28% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $1.26 | +1,249.21% | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $0.74 | +1,385.48% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $173.33 | +14.81% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $510 → $480 | $4.55 | +10,449.45% | 2 | Nov 3, 2020 |
BioMarin Pharmaceutical
May 2, 2025
Maintains: Neutral
Price Target: $82 → $78
Current: $54.60
Upside: +42.86%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $338 → $351
Current: $316.95
Upside: +10.74%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378 → $469
Current: $307.22
Upside: +52.66%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $30.35
Upside: +143.86%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $50.64
Upside: -24.96%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $49.55
Upside: -65.69%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $128.21
Upside: -28.24%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $61.93
Upside: -12.80%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $39.90
Upside: -12.28%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $1.26
Upside: +1,249.21%
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $0.74
Upside: +1,385.48%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $173.33
Upside: +14.81%
Nov 3, 2020
Maintains: Overweight
Price Target: $510 → $480
Current: $4.55
Upside: +10,449.45%